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Background
Marrow failure and subsequent pancytopenia result
from damage or suppression of pluripotent stem cells or
progenitor cells, induced by drugs or viral infection.
Physiologically, after the age of 65, bone marrow declines
by an intrinsic reduction in cells with an increase of fat,
displacing until replacement the hematologic tissue. Cyto-
penia may be severe and clinically significant in elderly
patients with chronic C infection during alpha peginter-
feron based treatments.
Methods
Ten patients, over the age of 65 (8 women and 2 men),
were treated with standard peginterferon alpha 2a and
ribavirin for 48 weeks. We scheduled biweekly visits dur-
ing the first month and then monthly during the rest of
the treatment period, as well during the initial 24-week
follow-up. At each visit we performed physical examina-
tion, biochemical and hematologic tests and noted
adverse events.
Results
Only women developed severe pancytopenia - 3 patients.
After the first month, hemoglobin (Hb) decreased with
1.4 g/dL. At month three, the complete blood count
(CBC) showed pancytopenia with a mean platelet count
of 72,000/cmm, mean Hb 9.9 g/dL, and mean leucocytes
2,000/cmm. The descending trend was constant, requir-
ing doses adjustments and the administration of growth
factors. In one patient, age 66, we discontinued the treat-
ment. In patients with no sign of liver cirrhosis bone
marrow exam was performed: it was hypocellular with
a large amount of fat cells and stroma. These patients
had a partial hematological response until the end of
treatment: mean Hb 10.1±1.6g/dL, WBC 2,800±1500/
cmm, platelets 56,000±20,000/cmm. Nine patients
achieved sustained virologic response. After treatment,
we decided an extended follow-up of to 5 years, marked
by periods of extreme asthenia and spontaneous bleed-
ings; there was no recovery of the cellular components of
the blood and in the bone marrow.
Conclusion
Despite frequent and severe hematological side effects,
elderly patients with chronic HCV can be treated
successfully with a standard-of-care regimen. Such
patients require careful monitoring of blood counts and
more supportive therapy.
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